End-stage liver disease complications
- PMID: 23429468
- DOI: 10.1097/MOG.0b013e32835f43b0
End-stage liver disease complications
Abstract
Purpose of review: Chronic liver disease causes significant morbidity and mortality because of any number of complications including hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemorrhage (EVH).
Recent findings: Predictors of response to lactulose, probiotics, and L-ornithine-L-aspartate therapy in minimal hepatic encephalopathy (MHE) have been reported. Although rifaximin was slightly more effective than lactulose in the maintenance of remission and decreased re-admission in patients with MHE, it was not as cost-effective as lactulose. Beta-blockade has been associated with paracentesis-induced circulatory dysfunction. Those who respond to nonselective beta-blockers have a predictable overall lower probability of developing ascites and HRS. Noradrenaline was as effective as terlipressin for the treatment of type 1 HRS and was less costly. Hemorrhagic ascites, defined as an ascitic fluid red blood cell (RBC) count of at least 10 000/μl, appeared to be a marker for poor outcome in patients with cirrhosis. In patients with acute EVH, band ligation, pharmacologic vasoconstrictors, and antibiotics are effective; notably, intravenous proton pump inhibitor therapy in lieu of vasoconstrictors achieved similar hemostatic effects with fewer side-effects.
Summary: Refinement in the clinical management strategies for patients with cirrhosis and its complications appear to continue to contribute to improved patient outcomes.
Similar articles
-
AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.Gastroenterology. 2024 Jan;166(1):202-210. doi: 10.1053/j.gastro.2023.10.016. Epub 2023 Nov 18. Gastroenterology. 2024. PMID: 37978969 Review.
-
Diagnosis and Management of Cirrhosis and Its Complications: A Review.JAMA. 2023 May 9;329(18):1589-1602. doi: 10.1001/jama.2023.5997. JAMA. 2023. PMID: 37159031 Free PMC article. Review.
-
Complications of cirrhosis.Curr Opin Gastroenterol. 2012 May;28(3):223-9. doi: 10.1097/MOG.0b013e328351d003. Curr Opin Gastroenterol. 2012. PMID: 22343347 Review.
-
Complications and outcomes in chronic liver disease.Curr Opin Gastroenterol. 2011 May;27(3):204-9. doi: 10.1097/MOG.0b013e3283460c7d. Curr Opin Gastroenterol. 2011. PMID: 21451410 Review.
-
Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.Adv Ther. 2008 Nov;25(11):1105-40. doi: 10.1007/s12325-008-0118-7. Adv Ther. 2008. PMID: 19018483 Review.
Cited by
-
LP340, a novel histone deacetylase inhibitor, decreases liver injury and fibrosis in mice: role of oxidative stress and microRNA-23a.Front Pharmacol. 2024 May 17;15:1386238. doi: 10.3389/fphar.2024.1386238. eCollection 2024. Front Pharmacol. 2024. PMID: 38828459 Free PMC article.
-
Effectiveness of Proton Pump Inhibitor Therapy in the Prevention of Bleeding After Prophylactic Endoscopic Variceal Band Ligation.Cureus. 2023 Jan 18;15(1):e33932. doi: 10.7759/cureus.33932. eCollection 2023 Jan. Cureus. 2023. PMID: 36819375 Free PMC article.
-
Organ-organ communication: The liver's perspective.Theranostics. 2021 Jan 16;11(7):3317-3330. doi: 10.7150/thno.55795. eCollection 2021. Theranostics. 2021. PMID: 33537089 Free PMC article. Review.
-
Coronary artery bypass graft combined with liver transplantation in patients with advanced alcoholic liver cirrhosis: A case report.Exp Ther Med. 2020 May;19(5):3197-3202. doi: 10.3892/etm.2020.8594. Epub 2020 Mar 11. Exp Ther Med. 2020. PMID: 32266015 Free PMC article.
-
Aldehyde dehydrogenase-2 activation by Alda-1 decreases necrosis and fibrosis after bile duct ligation in mice.Free Radic Biol Med. 2019 Dec;145:136-145. doi: 10.1016/j.freeradbiomed.2019.09.026. Epub 2019 Sep 23. Free Radic Biol Med. 2019. PMID: 31557514 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
